Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs
The acquisition is Samfara's first investment and is backed by a syndicate of European and North American institutional investors and family offices LONDON
Coverage
- Samfara completes acquisition of Chr. Olesen Synthesis
- Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs
- Samfara schließt die Übernahme von Chr. Olesen Synthesis, einem dänischen Hersteller von Wirkstoffen, die als kontrollierte Substanzen gelten, ab
- Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs
- Samfara completa la adquisición de Chr. Olesen Synthesis, fabricante danés de APIs sujetos a control